Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication

Crit Care. 2020 Jan 10;24(1):12. doi: 10.1186/s13054-019-2701-5.

Abstract

Background: Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high proportion of ventilated intensive care unit (ICU) patients. However, the clinical significance remains poorly defined. We investigated whether patients with ventilator-associated pneumonia not responding to antibiotics and in whom high levels of HSV could be detected in respiratory secretions benefit from acyclovir treatment.

Methods: Respiratory secretions (bronchoalveolar lavage fluid or tracheal aspirates) were tested for HSV replication by quantitative real-time PCR. ICU survival times, clinical parameters, and radiographic findings were retrospectively compared between untreated and acyclovir treated patients with high (> 105 HSV copies/mL) and low (103-105 HSV copies/mL) viral load.

Results: Fifty-seven low and 69 high viral load patients were identified. Fewer patients with high viral load responded to antibiotic treatment (12% compared to 40% of low load patients, p = 0.001). Acyclovir improved median ICU survival (8 vs 22 days, p = 0.014) and was associated with a significantly reduced hazard ratio for ICU death (HR = 0.31, 95% CI 0.11-0.92, p = 0.035) in high load patients only. Moreover, circulatory and pulmonary oxygenation function of high load patients improved significantly over the course of acyclovir treatment: mean norepinephrine doses decreased from 0.05 to 0.02 μg/kg body weight/min between days 0 and 6 of treatment (p = 0.049), and median PaO2/FiO2 ratio increased from 187 to 241 between day 3 and day 7 of treatment (p = 0.02). Chest radiographic findings also improved significantly (p < 0.001).

Conclusions: In patients with ventilator-associated pneumonia, antibiotic treatment failure, and high levels of HSV replication, acyclovir treatment was associated with a significantly longer time to death in the ICU and improved circulatory and pulmonary function. This suggests a causative role for HSV in this highly selected group of patients.

Keywords: Acyclovir; Bronchoalveolar lavage fluid; Real-time polymerase chain reaction; Simplexvirus; Ventilator-associated pneumonia.

MeSH terms

  • Acyclovir / therapeutic use*
  • Aged
  • Antiviral Agents / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Ventilator-Associated / epidemiology
  • Pneumonia, Ventilator-Associated / mortality*
  • Radiography / methods
  • Retrospective Studies
  • Simplexvirus / drug effects*
  • Simplexvirus / pathogenicity
  • Statistics, Nonparametric
  • Survival Analysis
  • Tomography, X-Ray Computed / methods

Substances

  • Antiviral Agents
  • Acyclovir